uniQure (NASDAQ:QURE – Get Rating) – Analysts at HC Wainwright dropped their Q2 2023 earnings estimates for uniQure in a report issued on Tuesday, May 16th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will earn ($0.96) per share for the quarter, down from their prior forecast of ($0.75). HC Wainwright has a “Buy” rating and a $90.00 price target on the stock. The consensus estimate for uniQure’s current full-year earnings is ($4.07) per share. HC Wainwright also issued estimates for uniQure’s Q3 2023 earnings at ($1.75) EPS, Q4 2023 earnings at ($1.75) EPS, FY2023 earnings at ($6.08) EPS, FY2024 earnings at ($3.86) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at $0.70 EPS and FY2027 earnings at $3.34 EPS.
uniQure (NASDAQ:QURE – Get Rating) last announced its earnings results on Monday, February 27th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.04. uniQure had a negative net margin of 143.01% and a negative return on equity of 35.03%. The business had revenue of $102.75 million during the quarter, compared to analysts’ expectations of $55.37 million.
uniQure Stock Performance
Shares of NASDAQ QURE opened at $20.72 on Thursday. The firm has a fifty day moving average price of $19.99 and a 200-day moving average price of $21.37. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.67 and a quick ratio of 6.56. The stock has a market cap of $985.86 million, a PE ratio of -6.20 and a beta of 1.18. uniQure has a 1 year low of $12.83 and a 1 year high of $28.25.
Insider Transactions at uniQure
In related news, CEO Matthew C. Kapusta sold 2,521 shares of uniQure stock in a transaction that occurred on Tuesday, March 7th. The shares were sold at an average price of $21.39, for a total value of $53,924.19. Following the completion of the sale, the chief executive officer now directly owns 468,743 shares in the company, valued at approximately $10,026,412.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 5,919 shares of company stock valued at $126,208 in the last 90 days. Insiders own 3.10% of the company’s stock.
Institutional Trading of uniQure
Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. lifted its stake in shares of uniQure by 14.0% in the 3rd quarter. BlackRock Inc. now owns 4,898,640 shares of the biotechnology company’s stock valued at $91,897,000 after purchasing an additional 599,805 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of uniQure by 11.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 4,259,886 shares of the biotechnology company’s stock valued at $79,915,000 after purchasing an additional 440,186 shares during the period. State Street Corp lifted its stake in shares of uniQure by 29.5% in the 3rd quarter. State Street Corp now owns 3,063,265 shares of the biotechnology company’s stock valued at $57,467,000 after purchasing an additional 698,121 shares during the period. PFM Health Sciences LP increased its holdings in uniQure by 7.0% in the 3rd quarter. PFM Health Sciences LP now owns 2,393,311 shares of the biotechnology company’s stock worth $44,899,000 after acquiring an additional 156,941 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in uniQure by 10.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,434,004 shares of the biotechnology company’s stock worth $26,903,000 after acquiring an additional 141,382 shares in the last quarter. 88.03% of the stock is currently owned by institutional investors and hedge funds.
About uniQure
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Featured Stories
- Get a free copy of the StockNews.com research report on uniQure (QURE)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
